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Abstract
When diagnosing sepsis, it is common to look for pathogens, microbe’s DNA, lipopolysac-
charide (LPS), or host biomarkers while missing out on microbiota. The next-generation 
sequencing of 16S rRNA gene allowed characterizing the gut microbiota taxonomy and 
clarifying the gut microbial population being more complex than was previously thought. 
We suppose that significant disruption of the microbiota is an indicator of the major role 
it plays in sepsis. Serious metabolic disorders of the gut microbiota may contribute to an 
unfavorable outcome in septic patients. With the changes not only in the composition but 
also in the metabolic activity of the gut microbiota taken into account, the characteristics 
of the mechanisms of interactions in the “septic” microbiome will allow the advances in 
the optimization of the diagnostics and therapy of sepsis to be made.
Keywords: sepsis, gut microbiome, critical states, aromatic microbial metabolites, 
metabolome, organ dysfunction
1. Introduction
In recent years, the microbiome has been considered as an important player in the pathophys-
iology of various types of diseases, including trauma and sepsis [1, 2]. Over 70% of species of 
microorganisms are nonculturable and cannot be isolated as a pure culture for identification. 
Omics technologies (genomics, transcriptomics, metagenomic sequencing, proteomics, and 
metabolomics) have fully changed our concepts about the composition and function of the 
“invisible organ” [3]. Widespread distribution of microbiomic studies became possible about 
10 years ago with the emergence of high-performance new-generation sequencing (NGS), 
allowing transcribing in mass the collective genome of microbiomes—metagenome. The 16S 
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rRNA gene encodes highly specific RNA of bacterial ribosomes and is present in genomes of 
all known microorganisms. Its structure is quite conservative, but variable-specific regions 
allow identifying microorganisms of different species and strains. The study pattern is quite 
simple but rather laborious: at the first stage, DNA is isolated from a sample, and then a 
so-called genome library containing copies of gene 16S rRNA belonging to different bacteria 
is obtained. The library is “read” using high-performance sequenators providing reception 
of several thousand nucleotide sequences of gene 16S rRNA for each sample. The next stage 
deals with analysis of a huge body of received data using bioinformatic techniques. Results 
are represented in a way most suitable in each particular case. The introduction of latest tech-
nologies, for example, nanopore sequencing, allows fast identification of bacteria in samples 
and finding markers of resistance to antimicrobial drugs within 5–10 minutes with the por-
table real-time device for DNA and RNA sequencing “MinION” that weighs less than 100 
grams. This method is currently undergoing clinical testing [4]. However, in a typical micro-
biome experiment, several aspects of microbial communities still remain inaccessible. These 
include low-abundance but potentially crucial taxa whose genetic material is not sampled by 
sequencing techniques due to being present below the level of detection [5]. The real value of 
all this novel knowledge to understand the pathogenesis of sepsis has yet to be established. In 
this chapter, we are discussing the important role of bacterial metabolites in comparison with 
taxonomic structure of the septic gut microbiota.
2. The gap between healthy and septic gut microbiomes
Sepsis is a multifaceted host response to an infecting pathogen that may be significantly 
amplified by endogenous factors [6]. The broader perspective also emphasizes the significant 
biological and clinical heterogeneity in affected individuals such as their age, underlying 
comorbidities, concurrent injuries (including surgery) and medications, and source of infec-
tion adding to further complexity [7]. The success of antibiotic treatment depends on rapid 
and accurate identification of relevant pathogens and is complicated by the increasing rate 
of antimicrobial resistance conditioned by the dynamic changes in the bacterial population 
in which aerobic and facultative anaerobic bacteria predominant at the onset of sepsis are 
replaced by anaerobic species as the oxygen levels deplete. Broad-spectrum therapy is admin-
istered in the absence of bacterial identification, but this may not accurately reflect causative 
pathogens [8].
For a better understanding of how to treat, we probably should change the paradigm from 
“anthropocentrism” to “microbiocentrism,” as we think.
The presence of over hundreds of species in the gut of a healthy adult host is a way to survive 
in an ever-changing world and the ability to receive energy from different sources of food. In 
critical condition, the advantage is obtained by those species that are capable of surviving 
in more extreme conditions with less oxygen and a lack of nutrients and trace elements. For 
example, Enterococcus is one of the few microorganisms capable of surviving and thriving in 
the presence of bile acids, an increased concentration (6.5%) of NaCl, hydrogen peroxide, and 
changes in the pH level [9]. The most frequent cause of abdominal sepsis is a leakage of fecal 
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material from the intestinal lumen into the peritoneal cavity [10]. The leakage introduces gut 
bacteria, including Enterobacteriaceae, Enterococcus spp., Streptococcus spp., and Staphylococcus 
spp., into the sterile peritoneal environment. Another prospective study of 32 patients admit-
ted to the ICU after the trauma and acute care surgery service similarly found a replacement 
of intestinal Faecalibacterium and Ruminococcus with the more pathogenic Enterococcus [11]. 
The site of infection is not usually in the gut, but the metabolic influence of the pathogens on 
the gut microbiota and host tends to be persistently overlooked. For example, microbes that 
flourished in the guts of elite athletes boosted the time that lab mice ran on a treadmill. These 
particular microbes seem to take lactate, pumped out by muscles during exercise, and turn it 
into a compound that may contribute to endurance [12].
In our preliminary study, we used gas chromatography-mass spectrometry (GC-MS) analysis 
of blood serum and feces simultaneously and at the same time analyzed the taxonomic com-
position of the gut microbiota using 16S rRNA gene-based metagenomic analysis in groups 
of patients with sepsis, n = 9, and healthy, n = 5. The sepsis was diagnosed according to the 
Sepsis 3 definition [7].
The taxonomic composition of the gut microbiota in a group at the phylum level as deter-
mined by the metagenomic analysis of feces is shown in Figure 1. The major four phyla of 
the human gut microbiota, Bacteroidetes, Firmicutes, Proteobacteria, Actinobacteria, were the 
predominant phyla in most patients. The composition of the gut microbiota was not stable 
in any of the patients, and dynamic changes were observed in all nine patients. At the same 
time, the absolute percentage of Proteobacteria in septic patients was several times higher than 
in healthy volunteers. This was confirmed at the family level. The Enterobacteriaceae family, 
which is a part of the Proteobacteria, was shown to represent the leading species among the 
top 10 in sepsis. However, clear understanding cannot be reached using only taxonomy since 
it allows to observe only a handful of processes taking place in the development of any infec-
tion (Figure 1).
As we have shown earlier, high levels of some aromatic microbial metabolites (AMMs) in serum 
are related to the severity and mortality of critically ill patients [13]. The sum of the level of 
eight most relevant metabolites, benzoic (BA), phenylpropionic (PhPA), phenyllactic (PhLA), 
p-hydroxyphenylbenzoic (p-HBA), p-hydroxyphenylacetic (p-HPhAA), p-hydroxyphenyl-
propionic (p-HPhPA), homovanillic (HVA), and p-hydroxyphenyllactic acids (p-HPhLA), in 
serum samples from septic patients was higher than in healthy people 3.7 (1.2–8.0) μM and 1.3 
(1.0–1.6) μM, respectively (p < 0.05). In the septic group, the maximum values of the sum of 
these metabolites were more than 10 μM which is higher than in patients with lethal outcome. 
The differences in the AMM quality profiles of simultaneously serum and fecal samples (SFS) 
of patients with sepsis and healthy are presented in Figure 2. The results showed that the feces 
of healthy people abound with such metabolites, p-PhAA, p-HPhPA, and p-HPhLA, support-
ing data obtained by Jenner et al. [14]. At the same time, we observed prevalence of BA, PhLA, 
and p-PhAA in sepsis with a higher level of BA in the gut of non-survivors. Differences in the 
proportion of AMM in the blood compared to the intestine can be explained by the fact that 
most hydrophilic (p-HPhAA, p-HPhLA, and PhLA) metabolites are excreted by the kidneys, 
while lipophilic metabolites (BA, PhAA, and PhPA) are absorbed by cells of tissue barriers 
(intestinal wall, lymphoid tissue, liver, vascular endothelium, etc.).
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In particular, serum samples of healthy people are characterized by a predominance of BA 
and PhPA, while hydrophilic AMMs are detected in sepsis with the appearance of high levels 
of HVA in the serum of non-survivors. BA is a product of the synthesis of bacteria, plants, 
and fungi, but a significant content is formed as a result of biodegradation of phenylalanine. 
Figure 2. Metabolic profile of aromatic metabolites in: (A) the gut and (B) the blood serum. The data are presented by 
median of the proportion of each acid among all AMMs.
Figure 1. Taxonomic composition of the gut microbiota by metagenomic analysis. Comparison the taxonomic 
composition of the gut microbiota: (a) at the major phylum and (b) by top 10 families.
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Experimental study of the proximal part of the gastrointestinal tract showed that BA had a 
bacteriostatic and bactericidal dose-dependent effect on coliform and lactic acid bacteria [15].
On the one hand, it is important to emphasize that the dysfunction of the microbiota is mani-
fested by excessive production of certain microbial metabolites as a reflection of the high micro-
bial load with pathological colonization by bacteria involved in the development of sepsis. On 
the other hand, microbiota function, which is very important for host homeostasis, such as 
microbial biodegradation of an excess of endogenous biologically active compounds, due to a 
decrease in biodiversity in the intestine, primarily a deficiency of indigenous anaerobes, is dis-
turbed [16]. The altered profile of aromatic metabolites in the blood may be an integral indicator 
reflecting these dramatic disturbances and possibly other functions of the “invisible organ.”
3. The gut microbial metabolites in the pathogenesis of sepsis
It was shown that in vitro some sepsis-associated AMM in clinically significant concentra-
tions can inhibit the phagocytic activity of neutrophils [17]; cause mitochondrial dysfunction 
[18]; influence on platelet aggregation [19]; reduce tyrosine hydroxylase activity, thus limit-
ing the synthesis of catecholamines; and participate in the pathogenesis of septic shock [20]. 
Numerous data obtained in vitro allow us to hypothesize that AMM acts as signaling mol-
ecules (Figure 3).
It is impossible to exclude the presence of common signaling pathways, cell receptors, 
transmembrane transporters, and other mechanisms of humans and bacteria, as well as the 
direct participation of microbial metabolites in the pathogenesis of sepsis. Thus, today, we 
should not confine ourselves to studying eukaryotic cells while searching for new molecu-
lar mechanisms of sepsis-associated organ failure and septic shock [20]. We should consider 
Figure 3. Schematic representation of levels of some biochemical parameters, metabolites, and hormones in blood serum 
in comparison.
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and simulate experimental changes in the internal environment of a person that occur with a 
radical “restructuring” of the microbiome in seriously ill patients. This approach opens new 
prospects for an objective monitoring of diseases, carrying out an assessment of the integral 
metabolic profile on common metabolites (particularly aromatic) within a given time, and 
will provide new targets for therapeutic effects in the future.
4. Microbiome-oriented therapy: how to keep balance?
In sepsis, disturbances of physiological parameters caused directly by patient’s conditions 
and multiple treatment-induced factors might have powerful impact on the gut microbiome. 
Finding a therapy aimed at restoring the balance between “beneficial” and “harmful” micro-
organisms is highly relevant. At present, there are several possible approaches (Table 1):
• Increase the “beneficial” microorganisms using pro-, pre-, and/or metabiotics.
• Use a combination of probiotics and prebiotics known as symbiotics.
• Improve the composition by transplantation of fecal microbiota transplantation (FMT).
• Suppress “harmful” microorganisms, and create favorable conditions for recovery of one’s 
own “beneficial” microorganisms using selective antibacterial drugs (similar selective 
digestive decontamination).
The undoubtful effectiveness of probiotics for correction of functional disorders of the gas-
trointestinal tract has been widely accepted. A randomized placebo-controlled study on 4556 
healthy newborns in India proved that oral probiotics Lactobacillus plantarum combined with 
fructo-oligosaccharides during the first postnatal week helped reduce sepsis incidence during 
the first 60 days of life [21]. A randomized, double-blind, placebo-controlled, experimental 
study of changes in the microbiome and intestinal barrier in early sepsis showed that probi-
otic intervention successfully modulates the microbiome and is therefore a promising tool for 
early intervention in sepsis [22]. At the same time, there are no recommendations for the use of 
probiotics in ICU yet. Present studies differ due to the diseases in patients, the microorganism 
strains used, and the prescribed dosage of probiotics. There is no consensus concerning the 
beginning and duration of treatment. As for today, the largest study of efficacy of probiotics 
and symbiotics in ICU patients was carried out by Manzanares et al. The sample of over 2700 
patients demonstrated that the use of probiotics for microbiota recovery reduced incidence of 
infectious complications (specifically, ventilation-associated pneumonias); it was possible to 
reduce the use of antibiotics without increasing mortality or length of stay in ICU [23].
In another study, the use of symbiotics as an adjuvant therapy in surgical patients reduced 
incidence of such postoperative complications as wound infection [24]. One of the reasons 
for doubts concerning expediency of applying probiotics in ICU is intestinal barrier failure 
in critically ill patients. The translocation of bacteria to systemic blood flow and lymph is 
known to promote a complex chain of events leading to multiple organ failure [34]. On this 
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Meta-analysis of 30 trials that 
enrolled 2972 critically ill patients
Different types of 
probiotic therapy
Probiotics were 
associated with a 
significant reduction 
in infections (risk ratio 
0.80, 95% confidence 
interval (CI) 0.68, 0.95, 
P = 0.009; heterogeneity 
I2 = 36%, P = 0.09)
☺ Kasatpibal 
et al. [24]
Meta-analysis of 31 articles that 
enrolled 2952 surgical patients





was the best regimen 
in reducing surgical 
site infection (SSI) 




298 patients with predicted severe 
acute pancreatitis
4 species of lactic 
bacterial (L. 
acidophilus, L. casei, 
L. salivarius, L. lactis), 
and 2 species of bifid 
bacteria (B. bifidum, 
B. lactis) in a dose of 
1010 daily
Probiotic prophylaxis 
is associated with 
an increased risk of 
mortality and higher 
rate of infectious 
complications
FMT
☺ Han et al. [26] Review of management of 
Clostridium difficile infection (CDI) 
with a focus on FMT
FMT The potential effective 
therapy but not enough 
data in the ICU patients
☺ Moayyedi 
et al. [27]
Meta-analysis of 5 trials that 
enrolled 284 patients with CDI
FMT (including 
autologous FMT)
FMT was statistically 
significantly more 
effective (RR, 0.41; 95% 
CI, 0.22–0.74; NNT, 
3; 95% CI, 2–7) than 
vancomycin or placebo
☺ McClave et al. 
[28]
Review of clinical use of fecal 
microbial transplantation in 
critical illness
FMT An attractive option to 
mitigate multiple organ 
dysfunction in the ICU
☺ FDA [29] Two immunocompromised 
patients
FMT The development of 
a severe infection and 
one death from fecal 
transplants containing 
drug-resistant bacteria
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basis, the use of live bioculture drugs (probiotics) in critically ill patients looks far from harm-
less and even dangerous. Possible, a NGS-based approach for the detection of bacteremia in 
patients with sepsis, which has shown promising results, will be a key step in the clinical 
use of NGS in this indication [35]. In randomized double-blind placebo-controlled indepen-
dent study on severe acute pancreatitis patients (n = 298)—Probiotics in Pancreatitis Trial 
(PROPATRIA)—1 group (n = 153), for prophylaxis of suppurative complications received 
a biomedicine containing 4 species of lactic bacterial (L. acidophilus, L. casei, L. salivarius, L. 
lactis) and 2 species of bifid bacteria (B. bifidum, B. lactis) in a dose of 1010 daily, while the 
control group (n = 145) received placebo. The results disappointed the researches: in the 
group of patients who received probiotics, more severe course of the disease was recorded, 
necrotizing pancreatitis developed more frequently, secondary bacteremia and other infec-
tious complications occurred, multiple organ failure developed reliably more frequently, and 
mortality was higher (р = 0.01). The authors of the study were unable to provide convincing 
explanations but expressed their doubts concerning reasonability for use of probiotics in 
critically ill patients [25].
In our opinion, the use of live microbial cultures of lactic acid bacteria might have aggravated 
metabolic disturbances and led to adverse consequences in initially severe patients, in par-
ticular, because of excessive production of PhLA and p-HPhLA which are typical metabolites 
of bifido- and lactic bacteria [36, 37]. A group of authors who used probiotics with positive 
effect in short bowel syndrome patients have reached similar conclusions, namely, the impor-
tance of metabolic status evaluation. The colleagues associated high mortality in PROPATRIA 
Study Population Type of intervention Results
SDD
☺ Price et al. 
[30]
Meta-analysis of 29 articles that 
enrolled patients in general 
intensive care units
SDD Favorable effect on 
mortality, with a direct 
evidence odds ratio of 
0.73 (95% confidence 
interval 0.64 to 0.84)
☺ Buelow et al. 
[31]
10 ICU patients SDD The limited risks for 
antibiotic resistance
SDD related
☺ Webster et al. 
[32]
Meta-analysis of 37 trials 
(involving more than 7000 
patients)
SDD SDD reduces ventilator-
associated pneumonia 
(odds ratio (OR) = 0.28; 
95% confidence interval 
(CI) = 0.20–0.38) and 
mortality (OR = 0.73; 
CI = 0.64–0.84)




56 patients with pneumonia or 
abdominal infection
Enteral correction of 
the metabolic activity 
of the gut microbiota
The downward trend of 
mortality by 11%
Table 1. Generalized data on the possible current use of microbiome therapy.
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study with lethal combination of proteolytic enzymes of pancreas and high level of lactic acid 
caused by bacterial fermentation of carbohydrates as a key factor related to intake of probi-
otics. Nevertheless, authors suggest that a probiotic therapy may not be counterindicated 
for the prevention of secondary infections associated with acute pancreatitis, provided that 
future clinical studies start probiotic therapy early as possible and prevent bacterial over-
growth not only of patient’s own intestinal flora but also the dose of probiotic bacteria [38].
An alternative to probiotics, “smart” direction, is infusion of liquid filtrate of feces from 
healthy fecal microbiota transplantation. The potential advantage of this method is enlarge-
ment of microbial biodiversity and the presence of biologically active substances and metabo-
lites, which might assist a longer effect of microbiota recovery [39]. This procedure has been 
successfully used for treating the severe infection caused by Clostridium difficile in more than 
1000 patients [26]. The recent meta-analysis (n = 284) has shown that FMT is significantly 
more effective in the treatment of such patients compared to the control group in spite of 
heterogeneity of groups due to the study sites (Europe vs. North America) and method of 
administration [27]. However, the current experience of FMT application in ICU is limited just 
to a few patients described only in sporadic publications [28]. The limited quantity of data, 
absence of objective criteria for efficacy evaluation, and insufficient knowledge of microbiota 
composition dynamics and its metabolic activity preclude wide application of this method 
in such vulnerable group of patients. The FDA does not currently approve of any use of 
fecal transplants. Two patients contracted severe infections, and one of them died, from fecal 
transplants that contained drug-resistant bacteria [29]. Putting it in another way, given the 
knowledge and risks, the use of FMT in critically ill patients can be compared to the first blood 
transfusion before the opening of the ABO system [19].
We assume that the main efforts in fighting infection should be directed to decrease microbial 
metabolic activity. Considering that the intestine is the main reservoir of bacteria and there-
fore the main source of bacterial metabolites, it seems appropriate to correct the activity of 
intestinal microbiota in patient with infection. Enteral correction of the metabolic activity of 
intestinal microbiota contributes to the improvement of the patients’ state [33].
Selective digestive decontamination (SDD) is often considered a prophylactic mode of anti-
biotic therapy allowing targeted prevention of bowel colonization by “pathogenic” micro-
organisms. The effect is achieved thanks to the selective impact on potentially pathogenic 
aerobic and facultative aerobic bacteria by means of enteral administration of antibacterial 
drugs that do not suppress anaerobic microorganisms, thus creating conditions for recovery 
of microbiota balance and assisting its functioning even in the unfavorable environment in 
ICU. Currently, numerous clinical studies and meta-analyses have shown that SDD helps 
prevent hospital infection in ICU and reduce mortality [30]. Wide implementation of SDD 
was restricted, inter alia, because of fears of increasing resistance of nosocomial microorgan-
isms to antibiotics [31]; however, convincing data have been obtained confirming the absence 
of resistant bacterial growth at the background of selective decolonization. A number of major 
investigations are currently underway, and their authors are expected to give shortly new 
clinical recommendations concerning the use of this method in ICU [32]. The pronounced 
clinical effect may be associated with a change in the profile of microbial metabolites, which 
requires additional research.
Microbiota-Oriented Diagnostics and Therapy in Sepsis: Utopia or Necessity? 9
As shown above, the “harmful/beneficial” gut bacteria disbalance is frequently associated 
with nosocomial pathogens and adverse outcome. The influence of negative factors related to 
changed internal environment of the macroorganism, and rather aggressive therapy leads to a 
drastic change in the species diversity of microbiota [40] and, as a consequence, a disturbance 
of functional activity of microbial community and a development of the maximal disorders 
that may cause irreversible breakdowns of homeostasis and host body death. A “vicious 
circle” is created: disturbance of gut microbiome function in critically ill patients leads to 
overproduction of certain microbial metabolites, which, in turn, have pathological impact on 
macroorganism’s organs and systems (Figure 4).
Two potential points of effect in sepsis treatment can be identified as:
1. Host state: prognosing negative dynamics of homeostasis indices as critical condition pro-
gresses and maximally sparing regimens of antimicrobial therapy taking into account the 
important role of microbiome
2. Treatment strategies: suppression of overgrowth and targeted correction of bacterial 
metabolism [41]
5. Conclusion
So, are the microbiota-oriented diagnostics and therapy in sepsis a utopia or necessity? In real 
clinical practice, it is not yet possible to provide real-time monitoring of the microbiome, due to 
such diagnostics being time-consuming, expensive, complex, and insufficiently studied. Previous 
works have noted that the gut is a “motor of multiple organ failure and sepsis” [42], and its 
Figure 4. Factors affecting the metabolism of microbiota in ICU [41].
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underestimation earned it a name of “forgotten organ.” In the past decades, the number of studies 
of microbiota in various diseases, including sepsis, has increased drastically and is likely to keep 
rising. Now it is clear that the “forgotten organ” is a reservoir of pathogens and possibly of genes 
associated with antibiotic resistance, as well as a marker of disease severity and outcome. Therapy 
aimed at restoring microbiota equilibrium rather than blindly prescribing broad-spectrum anti-
biotics may be the best choice. Understanding the metabolic language of microorganisms will 
serve as a catalyst for the development of new strategies, which will be especially important in 
the era of antibiotic resistance. New, culturally independent technologies allowing a fast accurate 
and comprehensive assessment of microbiome will be adapted in the coming years for practical 
use and wide application. Characterization of changes in ICU patient’s microbiome will enable 
advancement in the development of diagnostic and therapeutic interventions based on changes 
not only in the microbiota’s composition but also in its metabolic profile as well.
6. Methods
We used gas chromatography-mass spectrometry (GC-MS) method to quantify metabolites 
in human serum from septic patients and healthy volunteers. For taxonomic identification 
of samples, Ion 16S Metagenomics Kits, Ion Reporter metagenomic workflow solution, and 
Ion Torrent sequencing systems were used. Clinical and laboratory data and APACHE II 
and SOFA scores in patients were matched. Data were compared by Mann-Whitney U test; 
p-values less than 0.05 were considered significant.
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